CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results